ClinicalTrials.gg
Enrolling by invitationNCT06885424DESCENT-1Updated Nov 16, 2026

A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products

An observational study in Solid Tumor Cancer, Solid Tumor, Unspecified, Adult and Colorectal Carcinoma, sponsored by A2 Biotherapeutics Inc.. Enrolling by invitation at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by A2 Biotherapeutics Inc. · Observational

How we know

Updated Nov 16, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,342 studies in Colorectal Neoplasms with a site in United States — 415 open to participants now, 629 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
124th of 325
400 · median 220
Started
2025
with 143 others
Observational
326 of 2,342
68 open now
Primary completion
2030-03
later than 579 of 627 live
Registered
2,130th of 2,342
by date

Among the 2,342 studies in Colorectal Neoplasms with a site in United States, this one is the 124th largest by planned enrollment of the 325 observational ones that give a count, is one of 144 that started in 2025, is one of 326 observational ones, reaches primary completion later than 579 of the 627 other live ones, and was the 2,130th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

415 of the 2,342 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

410 more — sign in →

All 415 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,342 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.

Read the detailed description

This is a long-term follow-up study designed to evaluate delayed safety events and long-term efficacy of A2 Bio GT products for participants who received any amount of A2 Bio GT products in a previous interventional study. No further interventional treatment is administered in this study.

Participants will enroll in this long-term follow-up study upon completion of 2 years of follow-up in the assigned interventional study in which they received treatment. Participants will be followed for up to 15 years after administration of A2 Bio GT product. This study will collect long-term safety and efficacy data as outlined by the FDA guidance for long-term follow-up for GT products.

03

Conditions studied

  • Solid Tumor Cancer
  • Solid Tumor, Unspecified, Adult
  • Colorectal Carcinoma
  • Colorectal Carcinoma (CRC)
  • Non Small Cell Lung Cancer
  • Small Cell Lung Cancer ( SCLC )
  • Pancreatic Cancer
  • NSCLC
  • Mesothelioma
  • Ovarian Cancer
  • Ovarian Carcinoma
  • Head and Neck (HNSCC)
  • Head and Neck Cancer
  • Renal Cell Carcinoma (Kidney Cancer)
  • Triple Negative Breast Cancer (TNBC)

Keywords

  • CAR T Cell Therapy
  • Gene Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants previously treated on a A2 Bio GT study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Received any amount of A2 Bio GT product on a previous A2 Bio interventional study
  2. Able to provide written for this long-term follow-up study
  3. Able to comply with study requirements

Exclusion criteria

Exclusion Criteria:

1. There are no specific exclusion criteria for this study

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Participants that received A2 Bio GT products

    Other: No additional intervention administered in this long term follow-up study

Interventions

  • OtherNo additional intervention administered in this long term follow-up study

    Safety follow-up for A2 Bio GT products administered in a previous interventional study

06

What researchers measure

Primary outcomes

  1. Long-term safety of previous A2 Bio GT treatment

    Long-term safety of previous A2 Bio GT treatment as determined by incidence of adverse events (AEs)

    Time frame: 15 years post treatment with A2 Bio GT product

Secondary outcomes

  1. Overall survival

    The time from dosing of A2 Bio GT product to the date of death from any cause

    Time frame: 15 years post treatment with A2 Bio GT product

  2. Long-term durability of clinical effect of previous A2 Bio GT treatment

    Long-term durability of clinical effect of previous A2 Bio GT treatment as measured by duration of response (DOR)

    Time frame: 15 years post treatment with A2 Bio GT product

  3. Progression Free Survival (PFS)

    Time from dosing of A2 Bio GT products to the date of disease progression or death from any cause, whichever occurs earlier

    Time frame: 15 years post treatment with A2 Bio GT product

  4. Incidence of RCL detected in blood

    RCL will be tested on blood by ddPCR as applicable based on FDA guidance

    Time frame: 15 years post treatment with A2 Bio GT product

Other outcomes

  1. Progression Free Survival 2 (PFS2)

    Time from start of the next line of treatment after A2 Bio product to the date of disease progression or death from any cause, whichever occurs earlier

    Time frame: 15 years post treatment with A2 Bio GT product

  2. Persistence of of A2 Bio GT

    Amount of A2 Bio GT present in patients treated with A2 Bio GT as assessed by Polymerase Chain Reaction (PCR) (or similar method) on participant blood samples

    Time frame: 5 years post treatment with A2 Bio GT product

07

Study locations

5 sites
08

References and documents

Related links

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2030, 56 months after the start.

Of 117 industry-sponsored observational studies under Colorectal Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's planned 56 months is above that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Mar 20, 2025
StartActual
Jul 31, 2025
Primary completionEst.
Mar 31, 2030
CompletionEst.
Mar 31, 2040
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • UCSD Moores Cancer Center · La Jolla, United States
  • UCLA Medical Center · Los Angeles, United States
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    2 sites added
    Show 2 added (2 United States)
    • UCSD Moores Cancer Center · La Jolla, United States
    • UCLA Medical Center · Los Angeles, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06885424
Lead sponsor
A2 Biotherapeutics Inc.
Responsible party
Sponsor
First posted
Mar 20, 2025
Start date
Jul 31, 2025
Primary completion
Mar 31, 2030 (estimated)
Completion
Mar 31, 2040 (estimated)
Last update
Nov 16, 2026

Study contacts

Eric Ng, MD
study director · A2 Biotherapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion